In the four years since its launch, the precisionFDA platform has helped foster collaboration, further innovation, and develop regulatory standards for NGS-based drugs and devices. And now it has been recognized for the second year in a row for its contributions to advancing scientific research through providing a secure and collaborative online environment.
The precisionFDA platform was announced as a 2019 FedHealthIT Innovation Award Winner at a special reception on June 11 at the Washington Press Club, where more than 300 federal health leaders from government and industry gathered to recognize top innovation efforts from the federal health technology and consulting community. Nominated and chosen by our peers from across the federal health IT sector, the awardees were selected based on “driving innovation and results” at Veterans Affairs, Military Health, Health and Human Services, and Centers for Medicare & Medicaid Services.
“We are thrilled that precisionFDA has once again been recognized for creating an ecosystem in which members continue to contribute and innovate,” said DNAnexus’s Chief Cloud Officer, Omar Serang and member of the precisionFDA NGS sequencing team. “Its proven success has inspired other scientific partnerships, and we are proud to power portals that foster such innovative collaboration.”
PrecisionFDA is an online, cloud-based, virtual research space where members of the genomics community can experiment, share data and tools, collaborate, and define standards for evaluating and validating analytical pipelines. This open-source community platform, which has become a global reference standard for variant comparison, includes members from academia, industry, healthcare, and government, all working together to further innovation and develop regulatory standards for NGS-based drugs and devices. Launched in December 2015, the precisionFDA community includes nearly 5,000 users across 1,200 organizations, with more than 38 terabytes of genomic data stored.
Last year, the precisionFDA Next Generation Sequencing (NGS) Team received the FDA Commissioner’s Special Citation Award for Outstanding Achievement and Collaboration, which recognizes superior achievement of the Agency’s mission through teamwork, partnership, shared responsibility, and fostering collaboration to achieve the FDA goals.